Nigella Sativa as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia

Overview

Nigella sativa is the world's oldest immunomodulator. The main active component in Nigella sativa is thymoquinone. Research shows thymoquinone has antioxidant, anti-inflammatory, and antimicrobial effects. Based on these observations on the pharmacological activities of Nigella sativa, the potential therapeutic efficacy of N. Sativa was proposed in CAP.

The aim of this work is to assess the benefit of oral Nigella Sativa oil supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with pneumonia admitted to the Pulmonology Unit, Pediatric Department. Primary outcome: 1- The duration of clinical manifestations of pneumonia including time taken for normalization of respiratory rate, temperature, and oxygen. saturation, chest in drawing, hypoxia, lethargy, and inability to feed 2- The duration of hospital stay. Secondary outcome: 1. Discharge or death of the patient. 2. Occurrence of pneumonia complications.

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Central Contacts